Interprofessional collaboration is key to treatment optimization when managing advanced and metastatic forms of non-melanoma skin cancer (NMSC). This activity is a Q&A interview series with 6 multidisciplinary and interprofessional experts on immunotherapy in NMSC. Listen as they describe how they, as oncologists, dermatologists, nurses, and PAs work with their healthcare teams to integrate immunotherapy into their practice to help improve outcomes for patients with advanced/metastatic NMSC.
Upon completion of this activity, participants should be better able to:
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Physician Assistant, Seattle Cancer Care Alliance
Teaching Associate, University of Washington School of Medicine
Physician Assistant, UW Medicine
Medical Oncologist and Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Associate Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Academic Director, Mohs Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant Professor, Dermatology, Harvard Medical School
Department of Dermatology Brigham and Women’s Faulkner Hospital
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Shailender Bhatia, MD, has relevant financial relationships with 4SC, Agenus, Amphivena Therapeutics, Bristol Myers Squibb, EMD Serono, Exicure, Inc., Immune Design Corp, Incyte, Kuni Foundation, Merck, Nektar Therapeutics, Novartis, Regeneron (KNA Checkmate Pharmaceuticals), TriSalus Life Sciences, Xencor (Researcher).
Coley Doolittle-Amieva, MCMSc, PA, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Bristol Myers Squibb, Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Incyte, Merck, Pfizer, Regeneron, Sanofi Genzyme (Advisor); Kartos Therapeutics, NeoImmune Tech, Inc., Regeneron, Xilio Therapeutics (Grant/Research Support); Avstera Therapeutics, Checkpoint Therapeutics (Stock Options).
Vishal Patel, MD, has relevant financial relationships with Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Biofrontera, Regeneron, Sanofi, Sun Pharma (Advisor); LaRoche-Posey, Regeneron (Researcher); World Care Clinical (Independent Contractor).
Krista M. Rubin, MS, RN, FNP-BC, has no relevant financial relationship(s) with ineligible companies to disclose.
Emily S. Ruiz, MD, PhD, has relevant financial relationships with Checkpoint Therapeutics, Feldan Pharmaceuticals, Regeneron (Consultant); Castle Biosciences, Merk, Regeneron (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!*
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources